nafamostat has been researched along with Prostatic Neoplasms in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tomita, N | 1 |
| Kanamori, H | 1 |
| Fujita, H | 1 |
| Maruta, A | 1 |
| Naitoh, A | 1 |
| Nakamura, S | 1 |
| Ota, Y | 1 |
| Nozue, N | 1 |
| Kihara, M | 1 |
| Ishigatsubo, Y | 1 |
1 other study available for nafamostat and Prostatic Neoplasms
| Article | Year |
|---|---|
Granulomatous tubulointerstitial nephritis induced by all-trans retinoic acid.
Topics: Aged; Benzamidines; Dalteparin; Drug Administration Schedule; Gabexate; Guanidines; Humans; Idarubic | 2001 |